micro-community-banner
 
  • Saved

May 12, 2025
Associations Between Diabetes Mellitus and Neurodegenerative Diseases - PubMed

Associations Between Diabetes Mellitus and Neurodegenerative Diseases - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/39859258/

Diabetes mellitus (DM) and neurodegenerative diseases/disturbances are worldwide health problems. The most common chronic conditions diagnosed in persons 60 years and older are type 2 diabetes mellitus (T2DM) and cognitive...

Diabetes mellitus, especially T1DM and T2DM, is strongly linked to neurodegenerative diseases like AD, PD, HD, and ALS, possibly via insulin signaling disruptions, oxidative stress, and inflammation.

  • Saved

May 12, 2025
Neonatal diabetes mellitus around the world: Update 2024 - PubMed

Neonatal diabetes mellitus around the world: Update 2024 - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/39344692/

Neonatal diabetes mellitus (NDM), defined as diabetes with an onset during the first 6 months of life, is a rare form of monogenic diabetes. The initial publications on this condition...

Over 40 genes are now linked to neonatal diabetes mellitus, with recent discoveries expanding genetic and therapeutic insights through stem cell and CRISPR research into diverse disease mechanisms.

  • Saved

May 06, 2025
Vitamin D Supplementation: Shedding Light on the Role of the Sunshine Vitamin in the Prevention and Management of Type 2 Diabetes and Its Complications - PubMed

Vitamin D Supplementation: Shedding Light on the Role of the Sunshine Vitamin in the Prevention and Management of Type 2 Diabetes and Its Complications - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/39519484/

As the incidence of type 2 diabetes mellitus (T2DM) continues to increase globally, researchers are keen to investigate various interventions to mitigate its impact. Among these, vitamin D supplementation has...

Vitamin D supplementation may enhance glycemic control in type 2 diabetes by reducing inflammation, oxidative stress, and modulating cytokine profiles, supporting its use alongside anti-diabetic medications for improved outcomes.

  • Saved

May 06, 2025
Interventions for Type 2 Diabetes Prevention and Management Among Indigenous Children and Youth: A Systematic Review - PubMed

Interventions for Type 2 Diabetes Prevention and Management Among Indigenous Children and Youth: A Systematic Review - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/39803793/

This review highlights the urgent need for more research to address T2DM among Indigenous youth. Future research should prioritise culturally appropriate, long-term interventions that engage communities and empower Indigenous youth...

This systematic review found that culturally responsive, often school- and community-based interventions showed positive impacts on Indigenous youth's diabetes outcomes, highlighting the need for longer-term, empowering approaches to effectively reduce T2DM risk.

  • Saved

May 05, 2025
What’s New in T2D? Highlights from the 2025 ADA Guidelines

The 2025 ADA guidelines introduce key updates that reflect the growing need for personalized, comprehensive diabetes care to address a broader patient population. Among the most notable changes, continuous glucose monitoring (CGM) is now recommended beyond insulin-treated individuals, particularly for adults with type 2 diabetes who are on glucose-lowering therapies who may benefit from real-time glucose insights to improve glycemic control and reduce variability. The guidelines also offer strategies to navigate medication shortages, incorporate additional classes of glucose-lowering agents with cardiovascular and renal benefits, and maintain weight-loss pharmacotherapy beyond initial goals to support long-term metabolic health.

As medication selection continues to evolve, the guidelines emphasize a patient-centered approach that prioritizes cardiovascular, renal, and metabolic health. Beyond glucose lowering, clinicians are encouraged to consider therapy combinations with demonstrated benefits in reducing cardiovascular risk, slowing kidney disease progression, and supporting sustained weight management. New cardiovascular findings reinforce the role of SGLT2 inhibitors, expanding their use in both preserved and reduced ejection fraction heart failure. The guidelines likewise encourage careful patient selection and ongoing monitoring for adverse effects. Additionally, lifestyle-based interventions such as structured nutrition plans, physical activity, and behavioral strategies remain core pillars in achieving metabolic targets.

How will these updates shape your management strategies for adults with type 2 diabetes, particularly in integrating advanced monitoring tools and optimizing heart and kidney protection?

  • May 05, 2025
    sglt 2 inhibitors are very useful to help improve multiple comorbidities and CGM use will help keep our diabetiics better controlled
  • May 05, 2025
    I've been practicing that way for a while now, so I would like to do a better job at focusing on small lifestyle changes that can make a big difference in the long run. SGLT2 meds are great and effective not just to lower A1C but do that while protecting the renal and cardiovascular systems.
  • May 04, 2025
    SGLT2 inhibitors continue to provide benefits for T2DM patients with not only A1c reduction but also reducing progression of CKD and proteinuria as well as reducing exacerbation and hospitalizations from Heart Failure. Along with CGM, diabetes will become easier to control and improve quality of life for patients that suffer from this condition
  • May 04, 2025
    Cgm will gradually be used also in noninsulin dependent diabetes and SGLT2i will increase in use as well as new coming oral GLP1RA analogues
  • May 04, 2025
    I agree with the summarized statements and guidelines wholeheartedly, however, while initiating every DM2 patient on CGM as part of their therapy is an extremely valuable treatment option, insurance companies do not seem to agree. I also agree SGLT-2s offer many advantages in one treatment option not previously seen in others. I have begun to prescribe these medications earlier in the algorithm than in recent years, and hopefully, with these guidleines, insurance companies will allow them to be used first line more often for appropriate patients, prior to metformin.
  • May 04, 2025
    Although the treatment landscape of DM2 continues to expand, the treatment of DM2 become simpler with the three main choices of therapeutics: SGLT2, GLP-1 and metformin. Unfortunately, insurance guidelines present unnecessary barriers for the institution of CGMs.
  • May 04, 2025
    We are at a privileged place in today's medical practice that we are able to look at comorbidities in our patients with T2DM and make choices for GLP-1RAs, SGLt2is with proven cardio-renal-metabolic benefits & self-management strategies and valuable information from CGMs.
  • May 04, 2025
    We are at a privileged place in today's medical practice that we are able to look at comorbidities in our patients with T2DM and make choices for GLP-1RAs, SGLt2is with proven cardio-renal-metabolic benefits & self-management strategies and valuable information from CGMs.
  • May 04, 2025
    I use SGLT2 inhibitors; Ozempic and Kerendia in patients with DM and CKD as all these agents have proven benefits in reducing progression of CKD and decreasing cardiovascular mortality in these patients. I frequently use CGM in patients wit Type 2 diabetes especially ones on Insulin but also patients not on Insulin therapy unless their insurance denies it.
  • May 04, 2025
    The current treatment plan for me will be more use of CGM , further risk assesments for renal and cardiovascular and implementation of SGLT-2 more frequent and earlier.

    Since i also like mounjaro over ozempic for better weight reduction, better hgaic control and better tolerability i will add the sglt-2 early for the added benefits.
  • May 04, 2025
    continous glucose monitoring for patients results in better care able patient to stay at goals in glycemia control
  • April 21, 2025
    CGMs , GLPs
  • April 21, 2025
    CGMs are the biggest revolution in the management of Diabetes and with their biofeedback has resulted in positive outcomes with behavior modification diet and exercise and now with OTC avaialability of them has gone to a different dimension altogether with patient being incharge of their glycemic control and gives the providers better and timely management and trouble shooting in optimal control at the same time SGLT-2 inhibitors initially introduced as diabetic meds have become the standard of care in CAD , CHF and CKD patients So the question we have to ask ourselves in management of T2D , CKD and CAD and CHF pts is why they can not be on SGLT-2 inhibitors as in these pts optimal consdierations should be given to get the pts on these meds ! great time to practice diabetology and for Primary Care with these meds and the tools their role has become more important and effective also minmizing the referrals to endo and have the opportunity to have the broad spectrum perspective of Cardiac and Renal Health as well !!!
  • April 21, 2025
    more data on benefit in type 1 as well
  • April 18, 2025
    sglt2 and kerendia are excellent for stopping microalbunia and ckd
  • April 15, 2025
    SGLT-2 inhibitors are medication with multiple indications, prevent progression ckd, decrease the risk of cardiovascular events, the use of uACR and gfr are improtant in the monitoring ckd, adjust treatment .